Sept 30 (Reuters) – Merck said on Wednesday its experimental drug met the main goal of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa, a chronic skin disease that
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
(Updates with Dangote, Kenyan president's comments in paragraphs 5-8 & 15, planned power plant in…
VIDEO SHOWS: TRAINING OF GERMAN NATIONAL SELECTION ON DAY AHEAD OF MATCH AGAINST SERBIA IN…
By Pete Schroeder WASHINGTON, Sept 30 (Reuters) - The U.S. Federal Reserve announced Wednesday it…
By Stephen Nellis SAN FRANCISCO, Sept 30 (Reuters) - Synopsys and Amazon Web Services on…
MADRID, Sept 30 (Reuters) - French President Emmanuel Macron said on Wednesday that if Britain…
VW BRAND HR CHIEF: OUR GOAL IS TO PREPARE VOLKSWAGEN FOR THE FUTURE (The article…